Shanghai Qinhe Biopharmaceutical Technology

Qinhe Bio is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of next-generation precision oncology therapies. The company utilizes its proprietary Smart-Link technology platform to create tumor-microenvironment-activated (TME-activated) drugs, which remain inactive in systemic circulation and are specifically triggered by enzymes within the tumor. This approach aims to significantly reduce systemic toxicity and expand the therapeutic window of potent anti-cancer agents, including antibodies, cytokines, and antibody-drug conjugates. Their lead programs target well-validated pathways such as PD-L1 and IL-15, with several candidates currently undergoing clinical evaluation. Qinhe Bio is backed by prominent venture capital firms and maintains a robust R&D facility in Zhangjiang Hi-Tech Park.